<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">MOEXIPRIL HYDROCHLORIDE</span><br/>(mo-ex'i-pril)<br/><span class="topboxtradename">Univasc<br/></span><b>Classifications:</b> <span class="classification">cardiovascular agent</span>; <span class="classification">angiotensin-converting enzyme inhibitor</span>; <span class="classification">antihypertensive</span><br/><b>Prototype: </b>Enalapril<br/><b>Pregnancy Category: </b>C (first trimester); D (second and third trimesters)<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>7.5 mg, 15 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>ACE inhibitor that results in decreased conversion of angiotensin I to angiotensin II. Results in decreased vasopressor activity
         and aldosterone secretion.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>ACE inhibition and decreased aldosterone secretion. Antihypertensive effect.</p>
<h1><a name="uses">Uses</a></h1>
<p>Hypertension.</p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>CHF, left ventricular dysfunction.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to moexipril; history of angioedema related to an ACE inhibitor; pregnancy [(category C) first trimester;
         (category D) second and third trimesters].
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Hypersensitivity to any other ACE inhibitor; renal impairment, renal artery stenosis, volume-depleted patients; hypertensive
         patient with CHF; history of autoimmune disease; severe liver dysfunction; immunosuppressed patients; hyperkalemia; patients
         undergoing surgery/anesthesia; preexisting neutropenia; concurrent lithium therapy; lactation. Safety and efficacy in children
         are not established.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Hypertension</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 7.5 mg once/d, may increase up to 30 mg/d in divided doses<br/><br/><span class="impairmenttitle">Renal Impairment</span><br/>Cl<sub>cr</sub> <img src="../images/special/lesserorequal.gif"/>40 mL/min: Start with 3.75 mg q.d. (also if patient is volume depleted or
               on diuretics)<br/><br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give 1 h before or 2 h after meals. Food greatly reduces absorption of moexipril.</li>
<li>May need to reduce starting dose 50% in patients with possible volume depletion or a history of renal insufficiency.</li>
<li>Store at 15°30° C (59°86° F).</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Headache, <span class="speceff-common">dizziness,</span> drowsiness, sleep disturbances, nervousness, anxiety, mood changes. <span class="typehead">CV:</span> Hypotension, chest pain, angina, peripheral edema, <span class="speceff-life">MI</span>, palpitations, arrhythmias. <span class="typehead">Endocrine:</span> Hyperkalemia. <span class="typehead">GI:</span> Diarrhea, nausea, dyspepsia, abdominal pain, taste disturbances, constipation, vomiting, dry mouth, pancreatitis. <span class="typehead">Urogenital:</span>  Urinary frequency, increased BUN and serum creatinine. <span class="typehead"> Hematologic:</span> Neutropenia, hemolytic anemia. <span class="typehead">Respiratory:</span> Cough, pharyngitis, rhinitis, flu-like symptoms. <span class="typehead">Skin:</span> <span class="speceff-life">Angioedema</span> (rare), rash, flushing. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> <b>Capsaicin</b> may exacerbate cough. <span class="classification">nsaid</span>s may reduce antihypertensive effects. May increase <b>lithium</b> levels and toxicity. <span class="classification">potassium supplements</span> and <span class="classification">potassium-sparing diuretics</span> may increase risk of hyperkalemia. <span class="typehead">Food:</span> Food greatly reduces absorption of moexipril. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Readily absorbed from GI tract; approximately 13% of active metabolite reaches systemic circulation; absorption greatly
      reduced by food. <span class="typehead">Onset:</span> 1 h. <span class="typehead">Duration:</span> 24 h. <span class="typehead">Distribution:</span> Approximately 50% protein bound. <span class="typehead">Metabolism:</span>  Metabolized in liver to moexiprilat (active metabolite). <span class="typehead">Elimination:</span> 13% excreted in urine, 53% excreted in feces. <span class="typehead">Half-Life:</span> 29 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor closely for systematic hypotension that may occur within 13 h of first dose, especially in those with high blood
            pressure, on a diuretic or restricted salt intake, or otherwise volume depleted.
         </li>
<li>Monitor BP and HR frequently during initiation of therapy, whenever a diuretic is added, and periodically throughout therapy.</li>
<li>Determine trough BP (just before next dose) before dose adjustments are made.</li>
<li>Lab tests: Monitor serum electrolytes, WBC with differential, Hct and Hgb, UA, and kidney and liver function tests periodically
            throughout therapy.
         </li>
<li>Supervise therapeutic response closely in patients with CHF.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report to physician immediately swelling around face or neck or in extremities.</li>
<li>Report S&amp;S of hypotension (e.g., dizziness, weakness, syncope); nonproductive cough; skin rash; flu-like symptoms; jaundice;
            irregular heartbeat or chest pains; and dehydration from vomiting, diarrhea, or diaphoresis.
         </li>
<li>Consult physician before using potassium-containing salt substitutes.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>